Fernando Kowacs

Fernando Kowacs

Auto-generated profile, based on publicly available information

Fernando Kowacs

Hospital Moinhos de Vento

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2009 in Cephalalgia
Verified
Journal Article
Closed access
PDF file
LQLp Queiroz
Lp Queiroz
MPMfp Peres
Mfp Peres
EPEj Piovesan
Ej Piovesan
FKF Kowacs
F Kowacs
MCMC Ciciarelli
MC Ciciarelli
EZE Zukerman
E Zukerman

1 May 2005 in Brain Research
Verified
Journal Article
Closed access
YKYolande E. Knight
Yolande E. Knight
JCJohn D. Classey
John D. Classey
MLMichele P. Lasalandra
Michele P. Lasalandra
SASimon Akerman
Simon Akerman
FKFernando Kowacs
Fernando Kowacs
PGPeter J. Goadsby
Peter J. Goadsby

1 May 2003 in Cephalalgia
Verified
Journal Article
Closed access
NGNj Giffin
Nj Giffin
FKF Kowacs
F Kowacs
VLV Libri
V Libri
PWP Williams
P Williams
PGPj Goadsby
Pj Goadsby
HKH Kaube
H Kaube

1 December 2008 in Cephalalgia
Verified
Journal Article
Closed access
PDF file
LQLp Queiroz
Lp Queiroz
MPMfp Peres
Mfp Peres
FKF Kowacs
F Kowacs
EPEj Piovesan
Ej Piovesan
MCMC Ciciarelli
MC Ciciarelli
EZE Zukerman
E Zukerman

5 January 2009 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Open access
PDF file
LQLuiz P. Queiroz
Luiz P. Queiroz
MPMario F.P. Peres
Mario F.P. Peres
EPElcio J. Piovesan
Elcio J. Piovesan
FKFernando Kowacs
Fernando Kowacs
MCMarcello C. Ciciarelli
Marcello C. Ciciarelli
EZEliova Zukerman
Eliova Zukerman
Objectives.— To estimate the 1‐year prevalence of tension‐type headache (TTH) and the degree of the association of TTH with some sociodemographic characteristics of a representative sample of the adult population of Brazil.Methods.— This was an observational, cross‐sectional, population‐based study. We conducted telephone interviews on 3848 people, aged 18‐79 years, randomly selected from the 27 states of Brazil. Trained lay interviewers administered the structured questionnaire. It included questions about the sociodemographic characteristics of the population, as well as questions about headache. The degree of the association was calculated through prevalence ratios, adjusted with Poisson regression by gender, age, years of education, marital status, household income, job status, body mass index (BMI), and physical exercise.Results.— The estimated 1‐year gender‐ and‐age‐adjusted prevalence of TTH was 13.0% (95% CI: 11.8‐14.2%); 15.4% in males and 9.5% in females. The prevalence of probable TTH was 22.6% (95% CI: 21.1‐24.1%). Most (86.2%) subjects reported episodic TTH; 6.4% had chronic TTH. The prevalence was higher at 18‐29 years of age (16.2%). TTH was 1.6 times more prevalent in men, and 1.54 times more in subjects with more than 11 years of education. There was no significant association of TTH with marital or job status, household income, BMI, and physical activity.Conclusion.— This is the first nationwide epidemiological study of TTH in Brazil. The overall prevalence of TTH in Brazil is low, at 13%. TTH is significantly more prevalent in males and subjects with higher education level.

1 July 2019 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
FKFernando Kowacs
Fernando Kowacs
CRCélia Aparecida de Paula Roesler
Célia Aparecida de Paula Roesler
EPElcio Piovesan
Elcio Piovesan
ESElder Machado Sarmento
Elder Machado Sarmento
HCHenrique Carneiro de Campos
Henrique Carneiro de Campos
MJMauro Eduardo Jurno
Mauro Eduardo Jurno
Chronic migraine poses a significant personal, social and economic burden and is characterized by headache present on 15 or more days per month for at least three months, with at least eight days of migrainous headache per month. It is frequently associated with analgesic or acute migraine medication overuse and this should not be overlooked. The present consensus was elaborated upon by a group of members of the Brazilian Headache Society in order to describe current evidence and to provide recommendations related to chronic migraine pharmacological and nonpharmacological treatment. Withdrawal strategies in medication overuse headache are also described, as well as treatment risks during pregnancy and breastfeeding. Oral topiramate and onabotulinum toxin A injections are the only treatments granted Class A recommendation, while valproate, gabapentin, and tizanidine received Class B recommendation, along with acupuncture, biofeedback, and mindfulness. The anti-CGRP or anti-CGRPr monoclonal antibodies, still unavailable in Brazil, are promising new drugs already approved elsewhere for migraine prophylactic treatment, the efficacy of which in chronic migraine is still to be definitively proven.